BRIEF-Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner

Reuters

Oct 27

BRIEF-<a href="https://laohu8.com/S/KZA.AU">Kazia Therapeutics</a> To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner

Oct 27 (Reuters) - Kazia Therapeutics Ltd KZIA.O:

KAZIA THERAPEUTICS TO REQUEST FDA TYPE C MEETING TO DISCUSS OVERALL SURVIVAL DATA IN GBM AND POTENTIAL NDA FILING IN ALIGNMENT WITH FDA INITIATIVE PROJECT FRONTRUNNER
KAZIA THERAPEUTICS LTD - SEEKS FDA FEEDBACK ON REGULATORY PATHWAY UNDER PROJECT FRONTRUNNER FOR PAXALISIB

Source text: ID:nPn3pk4FHa

Further company coverage: KZIA.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578564891"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578564891\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578564891?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578564891","market":"nz","top_or_hot":-1,"title":"BRIEF-Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner</title></head><body><p><span>Oct 27 (Reuters)</span><span> - </span>Kazia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd <span>KZIA.O</span>:</p><ul><li><p>KAZIA THERAPEUTICS TO REQUEST FDA TYPE C MEETING TO DISCUSS OVERALL SURVIVAL DATA IN GBM AND POTENTIAL NDA FILING IN ALIGNMENT WITH FDA INITIATIVE PROJECT FRONTRUNNER</p></li><li><p>KAZIA THERAPEUTICS LTD - SEEKS FDA <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> ON REGULATORY PATHWAY UNDER PROJECT FRONTRUNNER FOR PAXALISIB</p></li></ul><p>Source text: <span>ID:nPn3pk4FHa</span></p><p>Further company coverage: <span>KZIA.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-27 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner</title></head><body><p><span>Oct 27 (Reuters)</span><span> - </span>Kazia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd <span>KZIA.O</span>:</p><ul><li><p>KAZIA THERAPEUTICS TO REQUEST FDA TYPE C MEETING TO DISCUSS OVERALL SURVIVAL DATA IN GBM AND POTENTIAL NDA FILING IN ALIGNMENT WITH FDA INITIATIVE PROJECT FRONTRUNNER</p></li><li><p>KAZIA THERAPEUTICS LTD - SEEKS FDA <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> ON REGULATORY PATHWAY UNDER PROJECT FRONTRUNNER FOR PAXALISIB</p></li></ul><p>Source text: <span>ID:nPn3pk4FHa</span></p><p>Further company coverage: <span>KZIA.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KZIA","symbol_name":"Kazia Therapeutics Limited","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUA3SPB3W:1","article_id":"2578564891","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578564891","pubTimestamp":1761564231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project FrontrunnerOct 27 (Reuters) - Kazia The","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KZIA":"Kazia Therapeutics Limited","BK4139":"生物科技"},"translate_title":"简介-Kazia Therapeutics将请求FDA召开C型会议，讨论GBM的总体生存数据以及与FDA倡议项目领跑者一致的潜在NDA申报","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KZIA":0.9},"content_text":"BRIEF-Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project FrontrunnerOct 27 (Reuters) - Kazia Therapeutics Ltd KZIA.O:KAZIA THERAPEUTICS TO REQUEST FDA TYPE C MEETING TO DISCUSS OVERALL SURVIVAL DATA IN GBM AND POTENTIAL NDA FILING IN ALIGNMENT WITH FDA INITIATIVE PROJECT FRONTRUNNERKAZIA THERAPEUTICS LTD - SEEKS FDA FEEDBACK ON REGULATORY PATHWAY UNDER PROJECT FRONTRUNNER FOR PAXALISIBSource text: ID:nPn3pk4FHaFurther company coverage: KZIA.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}